%D8%AF%D9%8A%D9%83%D8%B3%D9%84%D8%A7%D9%86%D8%B2%D9%88%D8%A8%D8%B1%D8%A7%D8%B2%D9%88%D9%84%E0%A6%A1%E0%A7%87%E0%A6%95%E0%A7%8D%E0%A6%B8%E0%A6%B2%E0%A7%8D%E0%A6%AF%E0%A6%BE%E0%A6%A8%E0%A6%B8%E0%A7%8B%E0%A6%AA%E0%A7%8D%E0%A6%B0%E0%A6%BE%E0%A6%9C%E0%A6%B2DexlansoprazoleDexlansoprazole%E0%AC%A1%E0%AD%87%E0%AC%95%E0%AD%8D%E0%AC%B8%E0%AC%B2%E0%AC%BE%E0%AC%A8%E0%AD%8D%E0%AC%B8%E0%AD%8B%E0%AC%AA%E0%AD%8D%E0%AC%B0%E0%AC%BE%E0%AC%9C%E0%AD%8B%E0%AC%B2DexlansoprazolDekslansoprazolDekslansoprazol%D0%94%D0%B5%D0%BA%D1%81%D0%BB%D0%B0%D0%BD%D1%81%D0%BE%D0%BF%D1%80%D0%B0%D0%B7%D0%BE%D0%BBDexlansoprazoleQ5268339%E5%8F%B3%E6%97%8B%E8%98%AD%E7%B4%A2%E6%8B%89%E5%94%91
about
P3781
A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult ParticipantsEfficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal ImpairmentMulticenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been HealedUse of Topical Budesonide in the Treatment of Eosinophilic EsophagitisStudy Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric HoarsenessDo Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment?Safety and Efficacy of Lansoprazole 30mg Twice Daily in Treatment of Laryngitis Associated With Gastroesophageal RefluxElucidation of Acid-Induced Pulmonary InflammationDoes Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?Effect of Proton Pump Inhibitor on Residual Platelet Reactivity After Clopidogrel in Homogenous Genetic StrataEfficacy Study of Ilaprazole to Treat Erosive EsophgitisHelicobacter Eradication Aspirin TrialEfficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. PyloriEfficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive EsophagitisLong-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose AspirinEfficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose AspirinEfficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal UlcerEfficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric UlcerEfficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive EsophagitisLansoprazole Tablets Special Drug Use Surveillance Gastroesophageal Reflux Disease With Dyspepsia SymptomsTwice Daily Prevacid for the Treatment of Laryngopharyngeal RefluxPharmacokinetics, Pharmacodynamics, Safety and Tolerability of After Administrations of DWP14012 Alone and Combinations of DWP14012, Clarithromycin and Amoxicillin in Healthy Male SubjectsComparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line TherapyDexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil HypertrophyEvaluating Treatment Response in Laryngo-Pharyngeal RefluxA New System for GERD Diagnosis and TreatmentTriple Therapy With Tegoprazan in H. Pylori Positive PatientsComparison of the Efficiency of Two Different PPI Formula in Atypical GERDA Randomized Trial Comparing Empirical and Guided Therapy for Unexplained Non-Cardiac Chest PainA Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive PatientsA Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 Milligram (mg) and 60 mg Delayed-release Capsules in Healthy Chinese ParticipantsA Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release CapsulesA Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast CancerAZD4635 Relative Bioavailability StudyA Study of LY2940680 in Healthy Participants (2012-09-30)Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn (2006-06-30)Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis (2005-12-31)
P4844
Q61729716-B5EEA9A0-3A47-4FDB-9CF7-B90C198B8664Q61894552-6E6538CB-C660-4F84-916E-561FDC497618Q61914501-BB1C565A-C6FF-4BAB-928E-8FCCA13BDA10Q61915123-29E55CE4-7C5A-4CB4-AA46-793C52635C91Q61915195-AA22CF38-25AB-4F5B-929C-D54BE1F796AAQ61915244-4CF9E781-F1E8-495C-BF9C-3FEFE80483F2Q61924781-4024F60E-190A-4B21-9182-0B570C147961Q61933577-0825CF53-7D02-48E6-9606-18BF0DA5F67CQ61934913-189B95C1-72B5-43A5-91C6-22FD037205BDQ61936851-7BF3E19F-F5D6-47EC-A9EF-E21AAFED5795Q61955745-2F33C028-D3EA-4870-B132-465F2B4CEBE4Q61956441-332B4010-6FCB-4292-82A5-AD1AC2FA5B28Q61956841-29D0A919-C5D9-4770-86B4-28F69BAE2AAEQ61957161-AAAAAC28-279D-46AD-8C9E-474EC1AC2525Q61965791-ED6DF8CD-2645-45B2-B5E7-3609167C7D51Q61966071-7AB06FC9-BA95-470B-B86F-32D74390AB65Q61966072-CEB30A69-7EEE-4A49-BF88-9BE02566B76BQ61967015-1CEC70E2-2898-407B-986C-E35E3CE311FFQ61967017-A6946297-8BD4-46C5-8AB9-85CA480371B6Q61967022-5EC1147A-8457-43D1-ACBE-A9AC54F52F48Q61967024-C24FBD85-B1EF-48E2-87F1-C79EDBFEE4CFQ61967026-1F0FF5DA-E305-4EE9-9626-95DCFD85E749Q61970104-E93A2177-744A-4E21-A11E-CF97CAE95216Q61981167-F3BD3B4C-432B-41D0-8C1A-E0375F409200Q62808922-B16F08F2-EC6F-444F-9FB5-4CFA59229FDEQ63320157-7514B905-2535-4BD6-9AA7-2BA7A98A59C4Q63338477-5AAD9BCA-8516-4C84-A88C-2C9DF4401E6BQ63338532-073D2D2B-43FE-472A-80EB-256226BD2588Q63394289-3ECCF829-7726-41C3-B7A4-739AAD1BE075Q63399851-2C778F89-A76B-44DC-9604-46F62DEF36C6Q63404219-7591723D-5DCE-4922-9BB8-DAD5FAF7672DQ63535030-E36FC548-DF8F-4D7D-9BCB-2985F273BE3FQ63535229-67E0B6FC-F595-4D32-8992-023D13F95479Q63535256-8E91E69D-6C41-43CC-9804-6F3713C9FD91Q63591529-3580899E-1CDE-416F-BFE4-C0F74F44D647Q63593402-27E43C5B-1776-4DAE-BDC4-135B3C48EC0EQ63599162-97E4C717-B5AF-46E3-A56C-8CEA96F6CAF0Q86168538-91B70018-6181-4451-961F-63483E058BCCQ86244693-6ED93AEF-7535-47EA-B509-E842AAB7C081Q86246807-9CB05E12-E4A6-4274-89D0-607432CEB5CD
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Dekslansoprazol
@sh
Dekslansoprazol
@sr
Dexlansoprazol
@ro
Dexlansoprazole
@vi
dekslansoprazol
@nn
dexilant 60 mg.
@pl
dexlansoprazole
@en
dexlansoprazole
@fr
Декслансопразол
@uk
Դեքսլանսոպրազոլ
@hy
type
label
Dekslansoprazol
@sh
Dekslansoprazol
@sr
Dexlansoprazol
@ro
Dexlansoprazole
@vi
dekslansoprazol
@nn
dexilant 60 mg.
@pl
dexlansoprazole
@en
dexlansoprazole
@fr
Декслансопразол
@uk
Դեքսլանսոպրազոլ
@hy
altLabel
(+)-lansoprazol
@en
(R)-lansoprazole
@en
2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
@en
Dexilant SoluTab®
@en
Dexilant®
@en
Dexlansoprazole
@en
Kapidex®
@en
T 168390
@en
TAK 390
@en
dexlansoprazol
@nn
prefLabel
Dekslansoprazol
@sh
Dekslansoprazol
@sr
Dexlansoprazol
@ro
Dexlansoprazole
@vi
dekslansoprazol
@nn
dexilant 60 mg.
@pl
dexlansoprazole
@en
dexlansoprazole
@fr
Декслансопразол
@uk
Դեքսլանսոպրազոլ
@hy
P2175
P486
P592
P6366
P661
P662
P665
P683
P2017
CC1=C(C=CN=C1C[S@@](=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
P2067
369.075882
P2115
N0000178337
P231
138530-94-6
P233
CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
P234
1S/C16H14F3N3O2S/c1-10-13(20-7 ...... 8-9H2,1H3,(H,21,22)/t25-/m1/s1
P235
MJIHNNLFOKEZEW-RUZDIDTESA-N
P267
P274
C₁₆H₁₄F₃N₃O₂S